Strides Pharma Science Limited (STAR) Earnings Call Transcript & Summary

July 29, 2025

National Stock Exchange of India IN Health Care Pharmaceuticals earnings 42 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and welcome to the Q1 FY26 earnings conference call for Strides Pharma Science Limited. Just a reminder that every participant line is listen-only, and once the presentation wraps up, you'll have a chance to ask questions. If you require help at any point during this call, please signal an operator by pressing star, then zero on your touchtone phone. Kindly be aware that this call is being recorded. With that, I'll now turn the conference over to Mr. Abhishek Singhal. Thank you, and over to you, sir.

Abhishek Singhal

executive
#2

Good evening, everyone, and thank you for being with us on this call covering Strides Pharma Science Limited's results for the first quarter of financial Q2 2026. Joining us today are Arun Kumar, our Founder and Non-Executive Chairperson; Badree Komandur, Managing Director and Group CEO; and Vikesh Kumar, Group CFO, who will walk you through the business highlights and the financials for the quarter. I trust you've had a chance to look at our results release and the quarterly investor presentation, both of which are available on our website and on the stock exchange website. A transcript of this call will be posted to the company's website within a week. Kindly note that today's discussion will be forward-looking in nature and must be reviewed in relation to the risks pertaining to our business. Should you have any further questions after this call ends, please don't hesitate to contact the Investor Relations team. I'll now turn the call over to Arun Kumar for his opening comments.

Arun Kumar

executive
#3

Thank you, Abhishek. Good afternoon, everyone. Good morning, and good evening to those joining us from every corner of India. We appreciate the time you're giving us today. I'm extremely pleased that we delivered another strong quarter, thanks to a disciplined and calibrated approach applied across the different line items of our business — with a focus on growth and, more importantly, on profitability, increased cash flow, and a much stronger balance sheet. We've now had several quarters of consistent performance, and I'm delighted that, despite the environment we operate in, we keep delivering strong and stellar results. I don't want to steal the thunder from the team that acts in justice on a daily basis — that is Badree and its leadership team. They're the ones taking the lead on today's call, and we're more than happy to address any questions that come forth after Badree's and Vikesh's insights in this session. Thank you.

Badree Komandur

executive
#4

Thank you. Welcome, everyone. I'm delighted to share Strides' quarterly earnings with you. I'll walk through all the growth metrics, and I'll hand things over to Vikesh for the profitability and efficiency measures of the performance — the Q1 performance. In this quarter, we closed at roughly INR 11.2 billion; that works out to about INR 720 crore. Gross margin widened by 300 basis points, which puts us at the 50% threshold. On an EBITDA basis, we stand at 19.5%, and operational EPS came in at 12.4. Our view is that operating leverage has begun to kick in, and operations are showing up modestly in our results. I'll go through every business, both on growth and on the reduction side in terms of profitability and efficiency. Where the U.S. market is concerned, we posted 10% year-on-year growth. Our long-term outlook for the business is $300 million to $400 million in 2028. We keep raising the business outlook. On a quarterly basis, the business grew and led the growth this quarter. We obtained one product approval and launched one product in FY26, and the total count of commercial products included synergy. Four products that did not meet our margin threshold were discontinued. We keep doing this quarter to quarter as part of our process initiative.

Badree Komandur

executive
#5

Our emphasis is on enhancing efficiency and profitability, and that work continues. On that basis, the decision was made to exit the four products. Market share held steady throughout the portfolio, we sit among the top three for critical products, and roughly 75% of the U.S. segment is covered by us. We keep funding R&D programs aimed at growth past $400 million, and the payoff from the whole R&D push will begin to show in upcoming quarters. Turning to the other aggregated markets, growth came in at 9.2%, or $42 million. In our view, the base has now been established. Going forward, growth in the other aggregated markets will become visible. Although year-on-year growth was 9.2%, it should improve considerably in the quarters ahead, largely because of product portfolio expansion and new customer acquisitions, both of which will fuel near-term growth. We feel we stand on very solid footing, and considerable time has also gone into regulatory work to reach a highly meaningful site. On the growth markets side, we performed well off a small base, with growth of almost 32.2%.

Badree Komandur

executive
#6

Access markets performed very strongly this quarter, driven by donor funding, and conditions remain difficult. When it comes to the growth markets, we think all the regulatory work is underway, and we expect that to produce growth in the near term. Looking at the long term, I believe the growth markets ought to do considerably better across a two to three-year span. We expect our portfolio maximization work on product selection to come through as it has in the US in the near term. With that, I'll hand it to Vikesh to cover profitability, efficiency, and the other balance sheet comments.

Vikesh Kumar

executive
#7

Thanks, Badree. Good evening, and good evening to everyone. I'm very pleased as well to report that Q1 came in with a truly stellar performance. We stay sharply focused on delivering growth quarter over quarter. Our approach to growth has been a very measured one, as Badree just noted. What we've concentrated on is bringing consistency to both profitability and efficiency results. You can see that reflected throughout the line items in our results. EBITDA stands at more than -INR 18 crore. That's up 15% year-on-year, and with an EBITDA margin of 19.5% for the quarter, this represents a very meaningful margin expansion, showing the strong operating leverage and margin improvement we continue to prioritize. On operating PAT, we're carrying forward the momentum built across the last few quarters, and it's very pleasing to report our highest ever quarterly operating PAT at INR 114 crore, a very good EBITDA to PAT conversion of 52%. For context, EBITDA to PAT conversion stood at 33% in Q1 of last year. That operating leverage is clearly visible here. With this, our operational EPS comes to INR 12.4 per share, which is 81% growth year-on-year.

Vikesh Kumar

executive
#8

On reported PAT, we also posted a very strong figure of INR 106 crore. I want to point out that in Q1 FY25 last year, we recorded a very significant one-time gain tied to the 1.6% stake that Strides still holds in OneSource. That showed up in last year's Q1 results. The gain was INR 102 crore, so operational PAT is really the right measure to use when looking at just PAT performance for this quarter. Operational cash flow for this quarter came in at about INR 118 crore, and that helped us generate free cash of INR 26 crore, which went toward debt reduction. Net debt now stands below INR 1,500 crore. It is at INR 1,496 crore. Forex had a negative impact on us of about INR 19 crore. Without that impact, net debt would have been lower by a further INR 19 crore. Our trailing 12-month EBITDA to net debt ratio is 1.8x. The cash-to-cash cycle is holding steady at 116 days, and ROCE improved by 20 basis points to 15.1% on a trailing 12-month basis. The capital employed we use to calculate ROCE includes the value of investments in OneSource, which is currently valued at INR 360 crore.

Vikesh Kumar

executive
#9

That investment has been left out of both our net debt and our ROCE calculation. Turning to operating expenses, they came in at 40.8% of sales for the quarter. Compared with the prior quarter, we brought operating cost down by INR 16 crore. Versus a year ago, that is an increase of roughly INR 43 crore. Net finance costs stood at INR 41 crore this quarter. That marks a decrease of INR 3 crore from the previous quarter and a substantial drop of INR 19 crore compared with last year. Our effective tax rate came in below 15% for this quarter, and for the remainder of the year we anticipate it landing between 17% and 20%. All in all, this was a very well-rounded operating performance, and we keep striving to build sustainable growth while staying focused on profitability and efficiency outcomes. Thank you, and we are ready to take your questions.

Operator

operator
#10

Thanks a lot. We’re moving into the question-and-answer portion now. If you’d like to ask something, you can press star and one on your touchtone phone. To take yourself out of the queue, press star and two. We ask that participants use their handsets when asking a question. Ladies and gentlemen, we’ll pause briefly while the queue is put together. Our first question is from Jagdeesh Sharma, an individual investor. Please go ahead.

Jagdeesh Sharma

analyst
#11

Hey there, and nice work on the strong quarter. I've got two fairly broad questions. First off, I'd like to ask about tariff exposure in U.S. manufacturing. Right now, what share of your sales is supplied by the Chestnut Ridge facility? And given possible tariff risk, does the price leave any room to adjust production? That's my first question.

Badree Komandur

executive
#12

Yeah. A third of our revenue is generated by the Chestnut Ridge facility, and the tariff remains something we have to keep an eye on. At the moment, the focus is that it's a stock covered gender, and we'll just have to wait and see how it plays out once any future announcements come from this fund.

Jagdeesh Sharma

analyst
#13

One-third of

Badree Komandur

executive
#14

Your top line.

Jagdeesh Sharma

analyst
#15

Alright.

Badree Komandur

executive
#16

At Chestnut Ridge, we've gone from running two shifts to just one. Should the need arise, we can lengthen that shift, and that will boost the capacity we have in Europe.

Jagdeesh Sharma

analyst
#17

Got it. My next question concerns the other regulatory markets. What is the wider growth plan for that other regulatory market segment? At what point should we expect this segment to achieve double-digit growth on its own, starting from where it stands now?

Badree Komandur

executive
#18

I'll begin with the other markets. There are a lot of markets out there. What we can say at this point is that the regulatory process is such that growth ought to begin picking up starting in the next quarter, and then over the following 2 to 3 quarters.

Jagdeesh Sharma

analyst
#19

Thanks. I really appreciate everyone hanging in there through all that waiting.

Operator

operator
#20

Thanks. Our following question is from Nitin Agarwal of DAM Capital. Kindly proceed. Hello, and thank you for taking my question; congratulations to the team on a strong quarter. Badree, regarding sales in the U.S. business, the quarter-over-quarter drop stems mostly from products being discontinued. How should we interpret that?

Badree Komandur

executive
#21

Yeah. Typically, that’s a pattern that’s been dominant over the past several quarters and several years. From Q4 into Q1, you get a short-lived dip, and after that growth accelerates in Q2, Q3, and Q4. Discontinuation has played a part in some of those portions as well. There’s also a certain degree of seasonality in that pattern. That’s just how it is. It’s very short-lived in nature. Okay. Second, building on that, in the market, are you observing any significant shifts in market dynamics that you’d want to highlight? Anything changing when it comes to less competition or different pricing behavior, given all the chatter about tariff risks that you’ve been seeing in the market? We aren’t seeing any trends like that right now. That’s why we’ve been able to hold our market share of 36 out of 73 products when it comes to the leading position. We’ll continue to keep watching as things develop. Moving on to this Beyond Generics, we’ve discussed filing the first incentive spray. If you could perhaps provide a bit more detail on this Beyond Generics strategy — how many, I mean, how many products are we aiming to file over the next two to three years, and when do they start to contribute?

Arun Kumar

executive
#22

To add to that, Arun. With the Beyond Generics strategy, what we’ve set out to do is essentially secure greater value per product and step up our investment in R&D. We have a very substantial pipeline of programs, and that includes 505(b)(2)s, the names of the entire domain, PACO, and also SIM. Those are three entirely new areas where we don’t currently operate. All of those are produced, or where we produce them, out of the U.S. We think we’ll reach a fairly meaningful price over the next three to four years while we more or less saturate the $400 million Generics strategy with a disciplined approach to pricing and margin control. The first product has been filed, but we will make at least three or four filings this year. We’ll also have our first batch, which will be ready for commercial operations by the end of the year, the end of this financial year. We have a series of filings in PACO and also in the nasal sprays space. We’re also strengthening our domain space there and also using or leveraging our controlled substances and factory capability at our Chestnut Ridge facility to move into more domains that require controls.

Arun Kumar

executive
#23

It's still early, though these are exciting times when it comes to deploying capital and growing that business. To build on what you asked, Badree, earlier, regarding the shifting environment — if we pulled products from the market lately because that was a need pushed here, we believe our pipeline is strong enough to keep the growth momentum going. As Badree correctly put it, we do have quite a bit of seasonality in our H2 space, which has been fairly standard for us over the last decade or so. That isn't anything new. Even 7% Q-o-Q growth is pretty nice growth from that angle, given that we've kept feeding products. On the whole, the only new trend we've observed is that nearly 50% of all releases approved haven't been launched. What that actually means is that while approvals keep arriving for products that would have been filed two to three years ago, a capital committee two to three years here is now seeing rational approaches. Manufacturers are making in-launching products, and they see there's no real value in being a product leader. That, in our view, is a positive trend, and also probably people are a little bit cautious about the tariff risks.

Arun Kumar

executive
#24

We firmly hold the view that they should not, and it could happen, and tariffs on generics are something the U.S. market simply cannot afford — though the conditions of the market we operate in could prove us wrong. I think, overall, through another effective step that sits between a mix of local manufacturing and, as Vikesh correctly noted, we can expand our ships. A great deal of our production can be shifted into the U.S. Of course, there is a cost attached. We will then balance the tariffs over time against local manufacturing costs. Overall, provided our gross margin trajectory stays the same, we have the flexibility of a very large fund that can be quickly tuned up to take additional volume, but also react to potential tariffs. We will have to wait and watch these next weeks as we come to a deadline in terms of timing. Overall, we continue to be very positive about the U.S. opportunity. Sorry about the long line in. No, thanks. That's very helpful. Just a couple of housekeeping ones. On the gross margin, 50.5, it's a pretty, you know, the best you've done in a while. Is this gross margin that's around 60 odd percent sustainable from here on?

Arun Kumar

executive
#25

So the real question is about overheads. How should we be thinking about overheads, starting from where we are today?

Vikesh Kumar

executive
#26

Apologies. Regarding gross margins, the mix of business has genuinely been a tailwind. As you can see, access market is at its lowest level we've ever had, and that has also contributed meaningfully to better gross margins. Even the product portfolio in the U.S. — the product mix there has helped us too. What we'd say is we would stay within the range. I think 58% to 60% is a solid range for us to stay in. On OpEx, even in the last quarter, we had said that, you know, H2 was a good run rate, and we'll keep going at that run rate. A INR 460, INR 470 crore per quarter is like a run rate — a good run rate for the model going forward?

Arun Kumar

executive
#27

Yes. Thanks a lot.

Operator

operator
#28

Thank you. Our next question is from Anjit Singh of Kotak Institutional Equities. Please go ahead. Can you hear me? Yes, you're coming through. I wanted to ask about the U.S. business. You've guided to $400 million in U.S. sales by 2028, which works out to a double-digit sales figure versus your 2025 days, yet looking at the first quarter numbers in constant currency, growth was only in single digits. Do you expect sales growth to speed up over the coming two or three quarters in the remaining years, or will it be more weighted toward the back end in 2010, 2026, 2027, 2028?

Badree Komandur

executive
#29

We're still holding to our long-term guidance of $400 million, and growth will definitely begin starting in Q2. We're not overly concerned about quarter on quarter as long as we hit that $400 million mark by FY2028. Okay. So basically, what you're saying is that growth will pick up from the second quarter onward. Sir, second, on your controlled substances strategy, is that already included in the $400 million guidance, or will it come on top of that?

Arun Kumar

executive
#30

Let me start with that. I think we shouldn't confuse this with the Beyond Generics strategy. What we're really saying is that right now we have a sufficient portfolio of unlaunched products — products that are approved but not yet launched — coming through our end-to-end acquisition, through other facility acquisitions, and/or from our own pipeline. We're in the process of revamping many of these products and launching them at the right, opportune moment. That is what will therefore get us to $400 million. It's simply a timing question. When do we launch a product? When do we discontinue a product? Beyond $400 million is more of an indication of the new R&D focus the company has on reaching domains and areas we have not been in before, which will drive growth beyond the $400 million. Will the two overlap? Maybe, maybe not. It's just to give a differentiation between the two that we will get to the $400 million mark. We don't see an issue with that, as was probably correctly alluded to. Will that have a few legs from the beyond $400 million, or is it all coming from our existing portfolio? It's academic. It's a moot point that isn't relevant to our growth strategy either. Awesome.

Arun Kumar

executive
#31

I appreciate that.

Operator

operator
#32

Thanks. Our upcoming question is from Pratik Kothari of Unique PMS. Go ahead, please.

Pratik Kothari

analyst
#33

Yes, hello, and good afternoon. Thanks. My first question is about the U.S. opportunity once more. First, you stated that competitors are, at least for the time being, acting rationally. Second, some reports indicate that the small molecules, particularly those losing patent protection, are too small to own for five years, in contrast with the prior five years. Given that, could you consider going past this $400 million as well within our generics portfolio, while keeping the Beyond Generics strategy separate? In other words, what would need to occur for you to reverse your position that we no longer wish to cap generics and that we will put money into R&D and secure additional products, considering what is opening up over the coming five years and how our peers are acting?

Arun Kumar

executive
#34

Right. Strides doesn't play in the first-wave generic game at all, basically. You're correct that the freedom-to-operate window is set to double over the coming 5 years, but unless it's a very specific area where we operate — which happens rarely — we stay out of first launches. We don't challenge, we don't do patent settlements, and being in that first wave isn't something we like. What we concentrate on is our strategy of finding products that are hard to make, scarce, difficult to develop, or that require clinical studies or these kinds of trials. That focus will stay. Which doesn't mean — the reason we give $400 million is that it's somewhat guarded, reflecting our disciplined approach to our product. If we were to launch the hundred-odd approved ANDAs and set out to become the next big Indian generic company, that would come at the expense of margin, and that isn't where our focus lies. Could sales exceed $400 million? The answer is no. Do we want to push for more than $400 million? The answer is no.

Pratik Kothari

analyst
#35

That's fair. During this quarter, do we — I mean, are there plans to increase what we spend on R&D mainly because of Beyond Generics? Is that already essentially upon us starting with this quarter?

Arun Kumar

executive
#36

Yes, that's already in place.

Pratik Kothari

analyst
#37

That’s fair. Thanks, and best of luck to you.

Operator

operator
#38

Thanks. Our next question is from Sarvesh Gupta with Maximal Capital. Go ahead, please.

Sarvesh Gupta

analyst
#39

Good evening, sir, and congratulations on a good set of numbers. Two questions. First, with this impending tariff, are we seeing increased sort of purchases from the U.S. to build up the inventory? Have we seen that behavior from our buyers? Second, on the Beyond Generics strategy, how much are we spending currently, which is baked in in our P&L or capitalized?

Arun Kumar

executive
#40

We haven't taken full advantage of that. If you look at what we spent overall this quarter, it comes to roughly INR 29 crore, and that covers both tangible and intangible capital.

Abhishek Singhal

executive
#41

All right, then — intangibles, that's R&D. All right, thanks.

Operator

operator
#42

Thanks. Our next question is from Suhal Mittal at MFC. Go ahead, please.

Suhan Mittal

analyst
#43

Hi there. Thanks, sir, for giving me the chance. I’ve just got 2 questions ready. First, this quarter we’re noticing a drag in CFO versus <<foreign_lang>> cash flow, and that’s a decline relative to the renovated conversion we posted in the prior quarter. Could you share any color on where that drag has shown up? Is it in the US, in the rest of the world markets, or in the actual growth markets?

Arun Kumar

executive
#44

That's solely attributable to a rise in inventory. Our inventories during the quarter have grown by roughly INR 70 odd crore, since we're building that up for our growth over the next nine months, you know.

Suhan Mittal

analyst
#45

Is that something you're thinking about for the short term, or should we be expecting the conversion rate to climb past 70 to 80% over the next several quarters, if we're speaking in qualitative terms?

Arun Kumar

executive
#46

Yes, it would move higher. I wouldn't put a number on that right now.

Suhan Mittal

analyst
#47

Alright. Alright, sir. Thanks.

Operator

operator
#48

Thanks. Our next question is from Prisam Mehta, an individual investor. Go ahead, please.

Prisam Mehta

unknown
#49

Hello, sir. I’d like to ask about growth markets. This quarter we’re seeing a strong 32% performance worldwide. What were the main drivers behind that, and which particular growth markets are producing this momentum? Should we expect a similar trajectory next quarter?

Badree Komandur

executive
#50

Right. Those growth markets look solid across a lot of regions — Canada, Brazil, and Africa, South Africa, all of those. As we see it, we've been ramping up our regulatory work considerably, and that will be the near-term focus. We believe this market is going to expand, since we've already pinpointed the products and have the portfolio maximization strategy in place.

Prisam Mehta

unknown
#51

Thanks.

Operator

operator
#52

Thanks. Our next question is from Kiran with Table 3. Please go ahead.

Kiran Dhanwada

analyst
#53

Thank you for the chance to speak, sir, and congratulations on such strong results. Sir, I have two questions — one strategic and one financial. On the strategic side, sir, in the annual report you discussed controlled substances, 505(b)(2), and nasal sprays quite a bit. You filed a nasal spray in April, the first one. Just on controlled substances, sir, as we look toward the next $100 million in the U.S., how does that business operate? Do we supply to the quota, or supply to a player who supplies to the quota? What are the broad EBITDA margins? For the next $100 million, should we assume roughly 20% to 30% of it will come from controlled substances? If you could give a bit more color on controlled substances, what margins we can make, and just the business model. At a very high level, again, we may not be specific, but that'd be great.

Badree Komandur

executive
#54

We lack the granularity regarding what we're pursuing as a policy. Information on products and quotas for controlled substances varies greatly from one organization to another, and this has been company policy for several years—we don't break it down to that level of detail. Understood, sir. Regarding the next $100 million, I see it's a rough ratio of how much. That's the average guidance of $400 million. Focus on that. I think that's it. Granularity around that isn't something we're willing to share with you. Sure. Sir, the pharma side—the partnership with Orbicular Pharma—we did that in May 2023. It's been a couple of years. The nasal spray we submitted, is that part of that Orbicular Pharma? Is that still active? Do we expect some filings out of it, just from qualitative insights? It is. The nasal spray system partnerships are with Orbicular. Got it. Got it. Last question, sir, from a financial perspective, what is the expected debt paydown in FY2026?

Arun Kumar

executive
#55

We're concentrating on producing three caps, and we stay dedicated to that concentration. We also have an investment in months of one valued at INR 360 crore, which represents the 1.6% space. If you make that adjustment already, then as far as net debt goes, we're in a very fairly comfortable position. Driving profitability and efficiency along with very calibrated growth remains our focus. That's what we'll keep concentrating on. Okay. Kevin, is there no expected debt paydown metric that you'd like to share? Three caps are in place — significant three caps. We are funding caps in R&D without any further borrowings. That will continue, and we ought to be able to bring the debt down. We know that when funding long-term, our own free cash is there. All the debt is tied to working capital, which is backed by receivables or inventory. In terms of our debt book, we're in a very comfortable situation, and given where we were four years ago, it's not something we really need to be apologetic about anymore. Perfect, sir. Understood. One last question on the qualitative aspect. Pricing challenges in the UK are something the presentation mentioned.

Arun Kumar

executive
#56

Could you give us a bit of detail on the pricing pressures in the UK and how those have impacted or will impact FY2026? I'm not asking about quarter to quarter — more broadly, what's the effect on FY2026? Q1 was an unusual quarter for us — I mean, Q1 really was an unusual quarter. In the UK markets, we did encounter some pricing headwinds. We believe those are temporary in nature, because it's not a visiting; you don't see it being rapid. We believe they're temporary in nature, and we should be able to bounce back strongly from this. Got it. Congratulations on all of this.

Operator

operator
#57

Thanks, and now we’ll take a question from Pranav Gandhi at Lotus Wells. Please go ahead.

Pranav Gandhi

analyst
#58

Well done on those strong results. I’d already gotten my question answered, so thank you very much.

Operator

operator
#59

Thanks. Our following question is from Shashi Kapoor at MoS Capital. The line is yours.

Shashi Kapoor

executive
#60

To start, I want to congratulate the whole team — Badree, Arun — outstanding results. Operations have been strong, and the stock is performing pretty well too. I have two questions. First, we should be generating roughly $400 to $500 million in free cash now. How would that be allocated between debt reduction and R&D? Second, what two or three risks do you see to the $400 million guidance we've provided? How do we plan to mitigate those risks? And last, if you look at us on an EBITDA basis, we're among the cheapest companies in the market. Maybe just a suggestion that we could look at strengthening our ties with the Investor Relations team in particular. We could bolster that team. Yeah, that's all.

Badree Komandur

executive
#61

On the first question, I’ll simply say that R&D and the R&D efforts will be stepped up, and debt is going to be kept inside a specific range. The aim is to repay the debt. We always view that from a long-term perspective. Our plan is to be debt-free within 3 to 4 years. That is what we intend to work on. If everything unfolds according to plan, then as we see it at this moment, it can be achieved. On risks, we are comfortable with risks. I think right now it is $290 to $400 trillion the fastest year. The products are known. 20 products could be launched each year. In addition, new opportunities are also coming through. I don’t cite any major risks at this moment. As for the complex concern, that is something every pharma company also has to focus on in order to get there. On our position, we don’t want to keep depending on the market dynamics—we have said software will go up and down. As far as we are concerned, our focus is on delivering shareholder value, which we have demonstrated in a meaningful way.

Badree Komandur

executive
#62

When certain matters have been unlucky across many years, that explains why our distribution to shareholders came to just $78.8 billion, done through demerger and listing. Our attention will stay on shareholder value.

Shashi Kapoor

executive
#63

Thank you. Many thanks.

Operator

operator
#64

Thanks. Our next question is from Darshil Zawedi at Crown Capital. Go ahead, please.

Darshil Zawedi

analyst
#65

Hi, sir. Congrats on a fantastic set of results. Most of my questions have already been covered. I just wanted to ask whether you have clear-cut guidance for U.S. sales — is there some kind of aspiration for the growth and access markets, sir?

Badree Komandur

executive
#66

There are still a handful of quarters left for us to dig into.

Darshil Zawedi

analyst
#67

All right, all right. I simply wanted to ask about the access market — this quarter it hasn't done what it typically does in any way, so is that cyclicality, or how should we view that going forward, sir?

Arun Kumar

executive
#68

What we're dealing with here relates more to the difficulties we've encountered when it comes to donor funding. As you're aware, that area is still difficult at this point. That unevenness is something we'll keep seeing, and we're still in ongoing conversations with the buyers.

Badree Komandur

executive
#69

I think the main thing worth knowing is that nearly 80% of the active market funding comes from USAID. For the antiretrovirals and malaria programs, USAID funding has been cut off entirely. Different countries and different agencies are obviously trying to fill that gap. The gap is too big. Right now, everything is up in the air, and I think across the industry you'll see demand drop significantly and other cancellations as well. It's a function of funding, and the funding is simply not there.

Darshil Zawedi

analyst
#70

That’s reasonable. I don’t see USAID moving forward at any point in the near term. I believe those markets — the growth markets — have enough time to offset it quite effectively. That was well handled, sir. I believe that covers everything on my end, sir. Wishing you all the best.

Operator

operator
#71

Thanks. Our next question is from Chirag Shah at White Pine Investment Management. Please go ahead.

Chirag Shah

analyst
#72

Hello there, and thank you very much for the chance to speak — and congratulations on the visitor figures. I have one quick question from my end. The first thing is gross margins. What would it take for margins to rise more sharply? We're sitting at roughly 60%, and we guided to 50% within a reasonable range on an annualized basis. Beyond the cracking jump that could occur and bring in extra margin, what's needed for us to lift it to, let's say, 60%?

Arun Kumar

executive
#73

I'd say no action is needed there, since we're sitting in a solid place at 58% to 60%. Going past that isn't something I see as feasible. You've got assorted cost structures, under-recovery implants, plus other inefficiencies that we'll be addressing. Assuming we could push above 50% is a bit much right now.

Chirag Shah

analyst
#74

Regarding the follow-up.

Operator

operator
#75

Chirag, could I get you to line up for a follow-up question?

Chirag Shah

analyst
#76

Alright.

Operator

operator
#77

Thanks. Our next question is from Mehtrisha at Sasir Capital. Go ahead. Hello. Hello. -Yeah, just one question about growth. This quarter, we did 7% Q-o-Q. Should we expect a quarter-on-quarter for the next couple of years? Is that right?

Badree Komandur

executive
#78

Revenue rose 6% compared with a year earlier. On a quarter-over-quarter basis it went down, but our attention stays on gross margins and EBITDA, and there you can actually observe how we performed both sequentially and versus the prior year. With EBITDA margins sitting at 19.5%, will those hold through the remainder of the year? Is that a reasonable assumption? We are striving to stay near that level. That is a fair answer. Thank you.

Operator

operator
#79

Thank you. Ladies and gentlemen, we'll treat that as today's final question. At this point, I'd like to pass the conference back to management for their closing remarks.

Badree Komandur

executive
#80

Appreciate it, everybody. As we concentrate on execution and expanding the business, we look forward to having your support. Thank you.

Operator

operator
#81

Thank you. That brings us to the end of this call on behalf of Strides Pharma Science Limited.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Strides Pharma Science Limited transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Strides Pharma Science Limited earnings transcripts and 131,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Strides Pharma Science Limited or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.